It’s no secret that the U.S. is now experiencing an Opioid crisis, with coverage of the issue even making international headlines. The fact that pharmaceutical companies don’t appear to be too bothered by the harm that its legal drugs are causing is also well-known. Now, New York City Mayor Bill de Blasio is giving these companies cause to be concerned with a major lawsuit.
According to the lawsuit, Mayor de Blasio is holding Big Pharma directly responsible for fueling the Opioid crisis, the New York Times reports. This is not the first time that the mayor of NYC is taking legal action against an entire industry, either, since he is also suing Big Oil for its huge role in making climate change the global threat that it is today.
In any case, the legal document pins many of the underlying problems that allowed the Opioid crisis to grow as much as it had on the companies making these drugs. Among the accusations that the lawsuit makes is the misrepresentation of these products as well as encouraging distributors to absolutely flood target cities with opioids.
The companies named in the lawsuit include Purdue Pharma, Teva, Cephalon, Johnson & Johnson, Janssen, Endo, Allergan, and Watson, which is a mix of both manufacturers and distributors. This isn’t the first time that a city actually sued entire industries over the harm that they caused with their products, either.
As Futurism reports, other cities and states have already taken legal action against Big Pharma. There are also examples in recent history that could play a role in how these procedures will go. In the 90s, for example, the tobacco industry was forced to make changes to how it markets its products following the 1998 Tobacco Master Settlement Agreement. If the NYC and other cities’ lawsuits pan out, the same changes could be seen in the pharmaceutical industry.


Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
NASA Partners with Katalyst to Save Swift Observatory with Innovative Docking Mission
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 



